Singapore markets closed
Straits Times Index
3,216.78 +11.96 (+0.37%) S&P 500
4,320.06 -9.94 (-0.23%) Dow
33,963.84 -106.56 (-0.31%) Nasdaq
13,211.81 -12.19 (-0.09%) Bitcoin USD
26,118.85 -490.53 (-1.84%) CMC Crypto 200
558.71 -9.34 (-1.64%)
CytomX Therapeutics Inc (6C1.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
As of 08:04AM CEST. Market open.
| Previous close | 1.2400 |
| Open | 1.1820 |
| Bid | 1.1700 x 0 |
| Ask | 1.1880 x 0 |
| Day's range | 1.1820 - 1.1820 |
| 52-week range | 1.1260 - 2.7510 |
| Volume | |
| Avg. volume | 315 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 Nov 2023 - 10 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksCytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksCytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksCytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
© 2023 Yahoo. All rights reserved.
